Abstract
The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.
| Original language | English |
|---|---|
| Pages (from-to) | 262-266 |
| Number of pages | 5 |
| Journal | Journal of Surgical Research |
| Volume | 46 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft. / Sakagami, Kenichi; Ohsaki, Toshihide; Ohnishi, Tetsuya; Saito, Shinya; Matsuoka, Junji; Orita, Kunzo.
In: Journal of Surgical Research, Vol. 46, No. 3, 1989, p. 262-266.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft
AU - Sakagami, Kenichi
AU - Ohsaki, Toshihide
AU - Ohnishi, Tetsuya
AU - Saito, Shinya
AU - Matsuoka, Junji
AU - Orita, Kunzo
PY - 1989
Y1 - 1989
N2 - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.
AB - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P <0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0024519190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024519190&partnerID=8YFLogxK
U2 - 10.1016/0022-4804(89)90068-1
DO - 10.1016/0022-4804(89)90068-1
M3 - Article
C2 - 2646474
AN - SCOPUS:0024519190
VL - 46
SP - 262
EP - 266
JO - Journal of Surgical Research
JF - Journal of Surgical Research
SN - 0022-4804
IS - 3
ER -